Biolyst › ALDXAldeyra Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma on December 15, 2026. There is 1 upcoming event on record.
Cash runway is approximately 50.5 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 34 concluded trials, 97% reached completion rather than being terminated or withdrawn.
Track ALDX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ALDX in the tracker
Recent history
Date Event Type Phase
September 29, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
July 30, 2026
8-K filed: Material agreement Corporate
—
July 15, 2026
8-K filed: Other event Filing
—
June 10, 2026
8-K filed: Leadership change, Reg FD disclosure Corporate
—
May 1, 2026
8-K filed: Reg FD disclosure Filing
—
April 20, 2026
8-K filed: Leadership change Corporate
—
April 1, 2026
8-K filed: Other event Filing
—
March 17, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
December 31, 2025
8-K filed: Leadership change Corporate
—
December 16, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 13, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
October 28, 2025
8-K filed: Other event Filing
—
July 17, 2025
8-K filed: Other event Filing
—
June 26, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
June 18, 2025
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) Trial Milestone
Phase 2
June 17, 2025
8-K filed: Other event Filing
—
May 6, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
April 17, 2025
8-K filed: Leadership change Corporate
—
February 27, 2025
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Trial Milestone
Phase 3
November 3, 2024
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Trial Milestone
Phase 3
June 11, 2024
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease Trial Milestone
Phase 3
November 21, 2023
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) Trial Milestone
Phase 2
June 23, 2023
A Study in Subjects With Retinitis Pigmentosa Trial Milestone
Phase 2
April 22, 2023
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Trial Milestone
Phase 3
April 13, 2023
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough Trial Milestone
Phase 2
October 11, 2022
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease Trial Milestone
Phase 3
June 14, 2022
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Trial Milestone
Phase 3
May 29, 2022
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels Trial Milestone
Phase 1/Phase 2
May 9, 2022
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease Trial Milestone
Phase 2
March 4, 2022
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.